Abstract
Introduction
Tumors of the salivary glands account for 3 to 6% of all head and neck neoplasm s in adults.' Their clinica l and histologic appearance varies ma rkedly. Mo st of these tumors (7 0 to 85 %) are found within the parotid g land . Among the parotid tumors, 25 % are malignant at diagnosis.I Carcinoid tumors are characterized by di stinct biologic, histologic , and functional properties, and they represent a unique, relatively uncommon sub set of neuroendocrine neoplasm s. Although approximately two-thirds of carcinoid tumors are identified within the gas trointestinal tract, it is well known that car cinoid tumors may arise within any anatomic loc ation that is popul ated with endoc rine or endocrine-like cells.' Carcinoid tumors are known to ari se in extragastrointestin allocations in exqui sitely rare cases, and such a findin g in the parotid gland is am ong the very rarest. Scattered rep ort s have documented the presence of parotid carcinoid tumors, but all such ca ses have been ass ociated with a primary carcinoid tumor elsewhere in the body."? After conducting an extensive searc h of the world literature, we report wh at to the best of our knowledge is the first case of a primary carcinoid tumor of the parotid gland. We detail the clinical, surgica l, radiologic , im munologic, and histo chemical findin gs associ ated with its diagnosis, and we de scribe our man agement of thi s case.
Case report
In November 1992, a 40-year-old man presented with a painless enlargement of his left face . He reported no oth er sympto ms or complaints . Inc isional biopsy initially revealed the presence of a parotid tumor, and it was extirp ated by superficial parot idectomy. On gros s examination , the specime n was mad e up of two portions of firm, tan-to-pink tissue that mea sured 0 .3 and 0.5 em in their greatest dimension. The tissue had a firm , yellow-to-pink cut surface. The tumor was initially ch aracterized as a ductal saliv ary gland car cinoma with solid and ba saloid patterns. Light microscopy revealed nestin g of the tum or cell s into cohesiv e groups of various sizes, with large, pleomorphic nuclei and granular cyt opl asm ( figure I , A) . Further immunohi sto chem ical an aly sis with neuroendocr ine markers stained strongly positiv e for chromo granin A and neuron-specific enolase, and the lesion was designated as an atyp ical carcinoid tumor ( figure I, B) . Electron microscopy further confirmed the diagnosis, demonstrating the presence ofnumerous neuroendocrine-type, dense-core, secretory granules that ranged in size from 350 to 400 nm and were mostly round in shape (figure 2).
When the patient initiall y presented in 1992, he had no other significant med ical history, and he was not taking any medication. His family history was notable for thyro id cancer in his moth er that was treated successfully with surger y and radio active iodine therapy. The patient denied any history of smoking or of radiati on expo sure durin g childhood. He did not have any symptoms suggestive of carc inoid syndrome, such as diarrhea, flushing , bronchospasm, or right-sided heart failure. Furthermore, he displayed no signs or symptoms of liver disease, such as prur itus, edema, or jaundice.
Two month s postoperatively, in Janu ary 1993, abdominal computed tomograph y (CT) detect ed two cont rast-enhancing hypoden se lesion s in the liver. Nuclear single-photon emission CT (usi ng tagg ed red blo od cell s) and percutaneous liver biop sy of the lesions revealed no evidence of malignancy. As a result , both lesion s were diagno sed as hepatic hemangiom as. At that time, a 24-h our level of urinary 5-hydroxyindol e acetic acid (5-HIAA), an excreted 534 by-product of serotonin degradation and a clinical marker of carcinoid disease, was within the ran ge of normal (2.0 to 8.0 mg124 hr). Normal level s were sub sequ ently documented in March, June, and July 1994 (figure 3). Findings on chest x-ray, bone sca n, small bowel x-rays, and upper and lowe r gastrointes tinal series were normal, and no lesions suggestive of primary or metastat ic disease were evident elsewh ere . Ser ial CTs over the next few years reve aled no change in the two liver mas ses, and annual urinary 5-HIAA level s remained within the normal range.
By July 1998 , however, the patient's urinary 5-HIAA level had become elev ated ( 10.3 mg124 hr) (figure 3), and he was referred to our clinic. We obt ained an octreotide scan, which revealed mult iple focal area s of isotope uptake in both the right and left lobe s of the liver; this finding is con sistent with somatostatin subtype-2-express ing hepati c metastatic disease . No evidence of abnormal uptake was observed in the region of the parotid gland on the left or right side or anywhere e lse in the body.
In September 2000, baseline measurements revealed that the patient had elevated serum levels of serotonin (I , I20 ng/ml ; normal : 55 to 260), chromogranin A (300 ng/rnl ; normal: 2.3 to 14.3), and pancre atic polypeptid e (307 pg/ml ; normal: 64 to 243); the substance P level ... neoplasms, is the most common benign neoplasm , while mucoepidermoid carcinoma accounts for most malignant lesions of the salivary glands. In fact , mucoepidermoid carcinoma is the most common salivary gland malignancy in children. Metastatic tumors of the salivary glands are typically melanomas (46 %) or squamous cell carcinomas (37 %), and a small percentage «I %) of metastatic lesions are carcinoid tumors arising mostly from a gastrointestinal primary."
Patients with malignant salivary gland neoplasms are usually older (55 to 65 yr), while those with benign neoplasms are usually somewhat younger (mean age: 45 yr) .' Most patients who present with carcinoid tumors are aged 60 to 65 years. ' The annual incidence of carcinoid tumors is similar to that of salivary gland tumors (2 to 3 per 100,000 population)." Two-thirds of these lesions occur in the gastrointestinal tract, while approximately 25 % occur in the tracheobronchopulmonary complex.
Although the risk factors associated with salivary gland neoplasia or carcinoid tumors are not well known, there is clearly an established relationship between radiation exposure and the development of salivary gland tumors; Schneider et al reported that 3% of patients who had been was normal ( figure 4 ). Yet despite clear biochemical and radiographic evidence of diffuse metastatic disease, the patient was clinically stable, in excellent condition, and without overt evidence of any disease. He declined therapeutic intervention, opting instead to be monitored regularly in the clinic.
In September 2001, the patient's serum serotonin and pancreatic polypeptide levels had risen even higher (1,386 ng/ml and 471 pg/ml, respectively), and his serum chromogranin A had more than tripled to 970 ng/ml (figure 4) . Abdominal ultrasound confirmed evidence of hepatic metastatic disease within the liver; the kidneys were normal.
One year later, a repeat octreotide scan demonstrated widespread metastatic foci in the liver with intense uptake; these findings were not appreciably different from the first scan. Again, the patient exhibited no evidence of any disease elsewhere, including the left parotid region . Repeat biochemistry revealed consistently elevated serum serotonin and chromogranin A levels (1,446 ng/ml and 1,050 ng/ml, respectively) (figure 4).
Despite evidence of disseminated disease, the patient nevertheless remained asymptomatic and in excellent condition, and he reported no diminution of performance status or quality oflife. He again declined any interventional therapy, including radiofrequency ablation, receptormediated isotope therapy, or liver resection.
Discussion
The reported annual incidence of salivary gland tumors is 1 to 3 per 100,000 population. ' 
As a consequence of its intri nsic slowly growing nature and the non specific prese nting sy mpto mato logy, the diagnosis of carcinoid tumors has often been made on ly as an inciden tal finding at surgery or autopsy. Fewer than 10% of pa tients wi th carcino id tumors act ua lly present with the classic "carcinoid syn drome," characterized clinically by the presence of flushing, diarrhea, ede ma, bronchospasm, and righ t-sided heart failure ; these find ings are usua lly indicative of hepatic metastatic carcinoid disease.IS Increases in our unders tanding ofcarcinoid tumors have led to sig nificant advances in diagnostic modalities .As a result, investigation and management have been considerably fac ilitated. In par ticular, oc treo tide scanning and analysis of distinctive serum markers-such as serotonin, chromogranin A, pancreatic polypeptide, and substance P-have enab led clinicians to better assess and mo nito r patient s with ca rcino id tumors. Further more, the widespread use of somatostatin analogues has augmented the therapeutic options for carci noid sy ndro me and prov ided sym pto matic re lief to these patients. 16 Un like the protean man ifestation s of carc inoi d disease, the presenting manifestation ofpatients with parotid tumors is usually a discre te, asymptomatic, so litary lump. In some circ um sta nces , pa in may be a fea ture and re flect invol veme nt (us ua lly ma lignant) of the facial nerve, whose lower branches course through the gland itse lf.3.6.7Asy mptomatic masses of the paroti d gland may also represent man ifestat ions of various inflammatory and infil trative diseases, includi ng sarcoidosis and Sjogren's syndrome, as we ll as salivary and branc hial cleft cysts. '? Be nign epit he lia l proliferation, most notably in the parotid gland, occ urs in 30 to 50 % of patients wi th Sjogren's syndrome, who common ly present with firm, no ntender gla nds.'? However, the parot id en largement in suc h patients may be epi sodic or diffuse, wh ich wo uld suggest an inflammatory et iolog y.
Facial nerve pa lsy in a patient with a paro tid mass is almost uni formly associated with ma lignancy, although sarcoid infiltr ation of the parotid gland is a we ll-know n In fact , one study demonstrated that women who developed a salivary gland tumor before the age of 35 years had a higher risk of bre ast cancer than did women with no history of sal ivary gland tu mor, altho ugh this relatio nship was not stati st ically sig nificant." Malignancies with in the parotid gland, particularly those of a neuroendocrine or igin, are ex tremely rare.' Nicod first described the presence of a carcinoid tumor associated with the paro tid in 1958.
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14 However, the technology at that time was not sop histicated eno ugh to ide ntify the pre se nce of a primary tumor elsewhere.
In the few other cases reported ' ? dur ing the late 20t h century, all described the presence of a carcinoid tu mor in the co ntex t of a pree xisting primary tumor that was diagnosed and subseque ntly treated years before the pat ient pre sen ted with a parotid lesion, suggesting that the parotid lesion represented a manifestation of metastatic carcinoid dise ase arising from a primary tumor elsewhere. Cha n 
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exce ption to this rule. Diagnostic investigation includes physical exam ination, CT,1 8.19 and fine-needle aspira tion biopsy.v -" Cytologic eva luation by means of electron microscopy can reliably co nfirm the diagnosis of a parotid malignancy, and immunohistoche mical analysis (using chromogranin A antibodies) may be particul arly useful in establishing the neuroend ocrine basis of the disease process." The overall sensitivity of fine-needle aspir ation biopsy for the detection of malignant cells in salivary gland tumors is variously reported as 87 to 94%, with a specific ity of75 to 100%.12. 25 Magnetic resonance imagin g has been proposed as useful in assessi ng the degree of soft-tissue involvem ent and perin eur al invasion." :"
Microscop ically, the struc ture of the salivary glands is similar to that of the pancrea s, with a duct system made up of acinar and duct cells ensco nced in a sheet of myoe pithelial cells. The acinar cells line the intercalated and striated ducts through which the saliva travels before it is expulsed into the mouth . While the salivary glands them selv es are mesoderm al in origin, endocrine ce lls may be found within these glands, most likely derived from embryoni c neur al crest cells of the diffuse neuroend ocrin e system. It is likely that such cells give rise to neuroendocrine tum ors in this location , although it has been proposed that pluripotent ial stem cells capable of dual epithelial and endocrine differenti ation may be the source of the tumor."
Unli ke secretions from other digestive orga ns popul ated with neur oendocrine cells (particularly the stomach, pancreas , and liver), where evidence exis ts for the paracrine regu lation of secretion, salivary gland secret ions are considere d to be predomin antly regulated by the autonomic nervous system. Current views maintain that the role of hormones in the salivar y glands-particularly aldostero ne and antidi uretic hormone-is solely to modi fy the ionic content of the saliva. Salivary secretion is reg ulated by either sympathetic or parasymp athetic stimulation, with the latter exhibiting a more dom inant influence. While the most co mmon mediators of salivary gland secretion are autonomic, neurons release vaso active intestinal polypeptide and substance P, thereby stimulating acinar cells to release calci um and secrete saliva."
One should be aware of the distinct anatomic and physiologic relationship of the salivary glands and pancreas when considering the genesis and behavior of carcinoid tumors in these locations. As early as 1798, Sommering recog nized this unique relationship when he referred to the pancreas as the "a bdo minal saliva ry gland.'?" Carcinoid tumors are known to derive from the neural cres t or neuroend ocrin e (APUD) tissues, although we are not certain whether APUD ce lls are present in normal salivary glands.29 Authors of reports of other neuroend ocrine tumors in the parot id gland have proposed that such tumors arise fro m neuroendocrin e stem cells that have migrated to the salivary gland from the neural crest" or possibly from ce lls of the Volume 85, Number 8 salivary duct syste m that have differentiated into cells with either neur oendocrin e or epithelial features." Wh ile our understand ing and characterization of the neuroendocrine functi on of the pancreas have evo lved, the presence and role of neuroe ndocr ine cells in the salivary glands have yet to be established or repor ted in the literature. The analogo us structural and functional pro perties of the two orga ns might sugges t similar neuroendocrine com positio n and regulation, although the significance and extent of their similarities remain unknown.
Carcinoids are often classifie d as typ ical (well-differentiated) and atypical (modera tely differentiated). The designation reflects the tumor 's clinica l features." For exa mple, atypical carc inoids are overtly malig nant tumors that behave more aggressively than typical carcinoid tumors (which are often indolent, beni gn neoplasms) and must therefore be managed accordingly."
Treatm ent of any parotid malignanc y is mainly surgical. Th e most successful interventi on is extirpation or debulking of the tumor by mea ns of a superficial or total parotidectomy. Preservation ofthe facia l nerve is indicated if a plane between the tumor and the nerve can be identified and if the nerve was functionally intact before surgery.'? For ben ign parotid neoplasms, simple enucleation of the tumo r is disco urage d because the incidence oflocal recurrence is high."
Adj unctive radiation or chemothera py may be useful,35.36 particul arly in patients in whom surgic al intervention is either co ntrai ndica ted or of limited utility-for exa mple, patients with metastatic disease, patient s of advanced age , and patient s who are unable to tolerate surge ry.' Adva nced sali vary gland tumo rs respond most favorably to postoperative fast neutron-beam radiation therapy, which may be used as the sole therapeuti c interventi on for unresectable tumors." Furtherm ore, Armstrong et al reported that patients with a stage III or IV salivary gland neoplasm who had undergone co mbined surgery and radiothera py had a higher rate of local control (5 1 vs. 17%) and a better prognosis (5-year surviva l: 51 vs. 10%) than did patien ts treated with surgery alone." However, it is interesting that combin ed therapy has demonstrated no benefit in patients with a stage I or II lesion. System ic che motherapy-most co mmo nly wit h cyclo phospha mide, doxorubi cin, and cisplatin-is typicall y reserved for metastatic or unresectable salivary gland cancers. Although these tumors are chemothera py-sensitive, chemotherape utic regimens are effective yet ephemera l, with response rates averagin g 40 to 50% and the average dur ation of responses rangi ng from 3 to 7 months.t"" Often highly aggressive , malignant tumors of the parotid gland are assoc iated with a poor prog nosis. Malata et al" reported 5-and 10-year survival rates of 68 and 49%, respectively, and Vander Poorten et al" reported a 5-year survival rate of 62%. Factors that have the most influence on prognosis include the tum or 's histopathol ogic type and stage, local tumor extensio n, and the pre sence or absence of facial nerve palsy. In particular, 10-year survival decreases with incre asing stage, with rates of 85, 69 , 43, and 14% correspo nding with stage I thro ugh IV lesions, respectively." Furth ermore, patients without local tum or extension have a more favora ble 1O-year survival (79 vs. 34%)}6 Finally, one series demonstrated no 8-year surv ival for patients with primary facial ner ve palsy; the 8-year survival rate obse rved in patients whose facial nerve was intact was 57 £70 }6
In genera l, pati ents with tumors in the major sali vary glands have a better prognosis than those with minor saliva ry gland lesion s. After treatm ent , patients must be followed for severa l year s becau se as many as 20 % of tumor recurrences develop after 5 years.
In patients with hepatic metastases, local resection , hepatic artery embo lization , or che moem bolization may be useful for co ntrol of liver disease.v-" Given the novelty of a carci noid tumor in this region , the utilit y of radioactive-labeled somatostatin analogues is not know n; in fact , it has yet to be ex plored. In ge nera l, surgical resection of carcinoid tumors, particularly among those that are localized, is assoc iated with relatively favorable 5-year survival rates.'
In conclusion, our case repre sents what to the best of our knowl edge is the first reported instance of a prim ary atypical ca rcino id tum or of the parot id gland. Despite its exquisite rarity, this newly charac ter ized disease entit y is of considerable interest to clinicians who evaluate any masses in the parotid regio n. Likewise, the possibility of a prim ary carcinoid tumor of the parotid gland ought to be considere d by any surgeo n who encounters a neoplasm of the parotid gland. Indeed , the managem ent of any carcinoid disease must include recogniti on of the possibility of metastatic spread to uncomm on anatomic locations, as secondary carcin oid tumors in the parotid gland have been described mu ltiple times in the literature. Alth ough a primary carci noid tum or of the parotid gland is extremely rare, the differential diagnosis of any parotid swe lling or mass ought to incl ude the possibility of carcinoi d tumor because timely recog nition and intervention are critica l for success ful treatment of this enigmatic disease.
